

Hiroshi Tomiyama, Ph.D.

President & CEO, Kotobuki Pharma

Areas of Expertise

- Medicinal Chemistry
- Pharmaceutical Engineering
- Pharmaceutical Business Strategy and Operations
- Accounting and Financial Analysis

Qualifications

1997: *Ph.D. in Pharmaceutical Sciences*, The University of Tokyo

1992: *Bachelor of Science in Pharmacy*, Tokyo University of Pharmacy and Life Sciences, Licensed Pharmacist, Japan

1990: *Certified Radiation Protection Officer* (obtained in the sophomore year of university)

Work Experience

2017–2019: *Part-time Lecturer in Medicinal Chemistry (Concurrent Appointment)*, Graduate School and Faculty of Pharmaceutical Sciences, Chiba University, Japan

2014–Present: *President & CEO, Kotobuki Pharma*

2007: *Appointed Executive Director, Kotobuki Pharma*

2000: *Joined Kotobuki Pharma as a research scientist*

1997–1999: Postdoctoral Researcher under the supervision of Professor Robert J. Linhardt, Division of Medicinal and Natural Products Chemistry (MNPC), College of Pharmacy, The University of Iowa, USA

Research Program: Synthesis of a Catabolically Stable C-Glycoside Analogue of a Cancer-Associated Carbohydrate Antigen for Cancer Vaccine Development

Awards

Awards in Medicinal Chemistry:

2015: **Breakthrough Award in Medicinal Chemistry**

Division of Medicinal Chemistry, Pharmaceutical Society of Japan

Title: Discovery of Ipragliflozin (Suglat®): A Potent and Selective Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor for the Treatment of type 2 Diabetes Mellitus

Awards in Pharmaceutical Engineering:

2025: **Encouragement Award for Invention**

Kanto Region Local Commendation for Invention, organized by the Japan Institute of Invention and Innovation ([JIII](#)).

Title of Innovation: Miniaturized Oral Tablet Designed for Water-Free Administration

— *Tramadol Hydrochloride OD Tablets 25mg/50mg "KO" for the Treatment of Cancer and Chronic Pain*

2022: **Grant-in-Aid Award**

The 21st Century Research Grant, Nagano Pharmaceutical Association

Project Title: Development of "KAWARA" Orally Disintegrating Tablets®: Easily Split by Hand and Easy to Swallow

Publications: Indexed under ScholarGPS® ID: 78182769548147 (Affiliation: Kotobuki Pharma)

Books and Book Chapters

2024 — *Modern Natural Product Synthesis: Overcoming Difficulties*. Foreword, Springer.

2008 — *Chemical Glycobiology: Synthesis and Evaluation of Anticancer Vaccine Candidates, C-Glycoside Analogs of STn and PSA*. In: American Chemical Society Symposium Series, Vol. 990, pp. 216–238.

Invited International Speaker (Lecture duration: 30 to 60 minutes)

Presentation Title: "A key turning point of SGLT2 Inhibitors; From O-glycoside to C-glycoside"

(2015: MRC Symposium, College of Pharmacy, Seoul National University, Korea)

Presentation Title: "Development of KT6-971: A C-glycoside of NPC1L1 transporter inhibitor"

(2011: Seminar at Kunming Institute of Botany, Chinese Academy of Sciences, China)

2010: 239th American Chemical Society National Meeting, Division of Medicinal Chemistry, San Francisco, USA)

Presentation Title: "Recent research on active tumor immunotherapy"

(2005: The 1st Symposium on Glycosaminoglycans, Natural Products Research Institute, College of Pharmacy, Seoul National University, Korea)

Pharmaceutical Engineering Patents Granted in Japan